New combo aims to shrink colon tumors before surgery
NCT ID NCT06890624
First seen May 30, 2026 · Last updated May 30, 2026
Summary
This study tests whether a stronger chemotherapy combination (Chinese modified FOLFOXIRI) plus an immunotherapy drug (PD-1 inhibitor) works better than standard chemotherapy (mFOLFOX6) before surgery for people with locally advanced colon cancer (stage II high-risk or stage III). About 138 adults will be randomly assigned to one of the two treatments. The main goal is to see if the stronger combo leads to more complete tumor disappearance by the time of surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLON CANCER (STAGE II & III) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.
Conditions inferred from the trial description
These were inferred from the trial's summary, not listed by the trial registrant.